Medicine guide

WEZENLA

As listed in the register: WEZENLA 90 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA

90 mg · solución inyectable

  • Prescription only
  • Cancer treatments and immune-system medicines
Active substance
Ustekinumab
Made by
Amgen Technology (Ireland) Unlimited Company

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

Medicine groupCancer treatments and immune-system medicinesL04AC05

Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet

How it works

From the US prescribing label for the same active substance (Stelara). It describes the substance, not this exact product.

Ustekinumab is a human IgG1қ monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines.

IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation.

Peak level after13.5 days
Half-life80.2 days
Mostly cleared after≈ 57 weeksfive half-lives — our arithmetic
PeakHalf gone57 weeks0
The shape is a standard model drawn from the two times above, not a measurement. How fast a medicine acts and wears off also depends on the dose, the form and the person.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-08

Safety of the active substance

From the US prescribing label for the same active substance (Stelara). It describes the substance, not this exact product.

Must not be used by
  • STELARA is contraindicated in patients with clinically significant hypersensitivity to any ustekinumab product or to any of the excipients in STELARA [see Warnings and Precautions (5.5) ].
  • Clinically significant hypersensitivity to any ustekinumab product or to any of the excipients in STELARA.
Most common side effects

The most frequently observed malignancies other than non-melanoma skin cancer during the clinical trials were: prostate, melanoma, colorectal and breast.

Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

European UnionNo exact match for this strength and form

CanadaNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byAmgen Technology (Ireland) Unlimited Company
Active substanceUstekinumab
Used inCancer treatments and immune-system medicines
Strength90 mg
Formsolución inyectable
ClassificationL04AC05 · Cancer treatments and immune-system medicines
Routevía subcutánea
MarketedYes, according to the register
BiosimilarYes — a biosimilar medicine, according to the register
Additional monitoring ▼Yes — under additional monitoring (black triangle). Report suspected side effects.
Name in the registerWEZENLA 90 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA
Nº Registro1241823003

Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician

Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.

Other strengths and forms

6 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.